Use of flucinolone acetonide for patients with diabetic macular oedema: patient selection criteria and early outcomes in real world setting

INTRODUCTION: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies. This approval was based on evidence from FAME trials which were conducted at a time when r...

Descripción completa

Detalles Bibliográficos
Autores principales: Elaraoud, Ibrahim, Andreatta, Walter, Kidess, Andrej, Bhatnagar, Ajay, Tsaloumas, Marie, Quhill, Fahad, Yang, Yit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700741/
https://www.ncbi.nlm.nih.gov/pubmed/26728265
http://dx.doi.org/10.1186/s12886-015-0178-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700741/
https://www.ncbi.nlm.nih.gov/pubmed/26728265
http://dx.doi.org/10.1186/s12886-015-0178-9

Ejemplares similares